Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Deferoxamine in aneurysmal subarachnoid hemorrhage
NL-OMON52890Phase 2Recruiting
- Sponsor
- Radboud University Medical Center
- Start
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of deferoxamine in subarachnoid hemorrhage (SAH), sponsored by Radboud University Medical Center. Primary endpoint: Occurrence of delayed cerebral ischemia. Started Dec 2022; status: recruiting.
02
Drugs
deferoxamine
03
Conditions
subarachnoid hemorrhage (SAH)
Beyond the preview
Go deeper on NL-OMON52890.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52890.